Rocket Net Income From Continuing Ops vs Ebit Analysis

RCKT Stock

USD 10.47 0.35 3.46%

Rocket Pharmaceuticals financial indicator trend analysis is much more than just breaking down Rocket Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Rocket Pharmaceuticals is a good investment. Please check the relationship between Rocket Pharmaceuticals Net Income From Continuing Ops and its Ebit accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rocket Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.

For more information on how to buy Rocket Stock please use our How to Invest in Rocket Pharmaceuticals guide.

Net Income From Continuing Ops vs Ebit

Net Income From Continuing Ops vs Ebit Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Rocket Pharmaceuticals Net Income From Continuing Ops account and Ebit. At this time, the significance of the direction appears to have totally related.

The correlation between Rocket Pharmaceuticals' Net Income From Continuing Ops and Ebit is 0.99. Overlapping area represents the amount of variation of Net Income From Continuing Ops that can explain the historical movement of Ebit in the same time period over historical financial statements of Rocket Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Rocket Pharmaceuticals' Net Income From Continuing Ops and Ebit is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Income From Continuing Ops of Rocket Pharmaceuticals are associated (or correlated) with its Ebit. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ebit has no effect on the direction of Net Income From Continuing Ops i.e., Rocket Pharmaceuticals' Net Income From Continuing Ops and Ebit go up and down completely randomly.

Correlation Coefficient

0.99

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Net Income From Continuing Ops

Ebit

Most indicators from Rocket Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Rocket Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rocket Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.

For more information on how to buy Rocket Stock please use our How to Invest in Rocket Pharmaceuticals guide.At this time, Rocket Pharmaceuticals' Selling General Administrative is comparatively stable compared to the past year. Enterprise Value is likely to gain to about 2.4 B in 2025, whereas Issuance Of Capital Stock is likely to drop slightly above 203.6 M in 2025.

	2022	2023	2024	2025 (projected)
Interest Expense	1.9M	1.9M	2.2M	3.3M
Depreciation And Amortization	6.3M	7.1M	8.2M	8.6M

Interest Expense Depreciation And Amortization

Rocket Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Other Liab	Net Tangible Assets	Other Assets	Long Term Debt
Total Assets		0.5	0.93	0.94	1.0	-0.57	-0.56	-0.85	0.23	0.67	0.94	0.77	0.92	0.97	0.97	-0.19	0.89	0.95	0.66	0.92	0.56	0.97	0.66	0.94	0.04	0.63
Short Long Term Debt Total	0.5		0.33	0.33	0.47	0.0	-0.45	-0.2	-0.05	0.63	0.28	0.4	0.6	0.51	0.39	0.54	0.56	0.33	0.69	0.6	0.18	0.41	-0.06	0.53	-0.46	0.89
Other Current Liab	0.93	0.33		0.99	0.92	-0.64	-0.21	-0.93	0.2	0.35	0.98	0.67	0.75	0.88	0.97	-0.24	0.68	0.98	0.64	0.75	0.37	0.96	0.87	0.78	0.34	0.52
Total Current Liabilities	0.94	0.33	0.99		0.94	-0.64	-0.27	-0.93	0.22	0.4	0.99	0.69	0.78	0.89	0.97	-0.23	0.73	0.98	0.65	0.78	0.46	0.96	0.86	0.8	0.32	0.5
Total Stockholder Equity	1.0	0.47	0.92	0.94		-0.57	-0.57	-0.85	0.25	0.68	0.94	0.76	0.92	0.98	0.97	-0.24	0.89	0.94	0.62	0.93	0.56	0.97	0.66	0.94	0.02	0.61
Current Deferred Revenue	-0.57	0.0	-0.64	-0.64	-0.57		0.09	0.71	-0.86	-0.11	-0.72	-0.43	-0.44	-0.53	-0.58	0.33	-0.52	-0.64	-0.33	-0.45	-0.3	-0.6	-0.78	-0.5	-0.41	-0.25
Net Debt	-0.56	-0.45	-0.21	-0.27	-0.57	0.09		0.15	-0.18	-0.96	-0.31	-0.57	-0.73	-0.58	-0.41	0.04	-0.78	-0.29	-0.26	-0.73	-0.64	-0.41	0.17	-0.72	0.54	-0.35
Retained Earnings	-0.85	-0.2	-0.93	-0.93	-0.85	0.71	0.15		-0.28	-0.24	-0.94	-0.57	-0.69	-0.79	-0.89	0.36	-0.63	-0.96	-0.52	-0.7	-0.34	-0.89	-0.88	-0.73	-0.29	-0.46
Accounts Payable	0.23	-0.05	0.2	0.22	0.25	-0.86	-0.18	-0.28		0.13	0.32	0.23	0.22	0.22	0.19	-0.21	0.37	0.23	0.08	0.22	0.24	0.22	0.36	0.26	0.17	0.11
Cash	0.67	0.63	0.35	0.4	0.68	-0.11	-0.96	-0.24	0.13		0.41	0.6	0.79	0.68	0.52	0.07	0.83	0.42	0.4	0.79	0.62	0.53	-0.07	0.77	-0.53	0.54
Non Current Assets Total	0.94	0.28	0.98	0.99	0.94	-0.72	-0.31	-0.94	0.32	0.41		0.71	0.78	0.9	0.97	-0.29	0.75	0.98	0.61	0.78	0.47	0.96	0.86	0.82	0.33	0.49
Non Currrent Assets Other	0.77	0.4	0.67	0.69	0.76	-0.43	-0.57	-0.57	0.23	0.6	0.71		0.81	0.77	0.76	0.05	0.78	0.66	0.71	0.81	0.47	0.73	0.42	0.81	0.06	0.47
Cash And Short Term Investments	0.92	0.6	0.75	0.78	0.92	-0.44	-0.73	-0.69	0.22	0.79	0.78	0.81		0.92	0.84	-0.11	0.96	0.79	0.68	1.0	0.59	0.86	0.41	1.0	-0.2	0.67
Common Stock Total Equity	0.97	0.51	0.88	0.89	0.98	-0.53	-0.58	-0.79	0.22	0.68	0.9	0.77	0.92		0.95	-0.24	0.87	0.9	0.58	0.92	0.44	0.97	0.6	0.94	-0.03	0.66
Common Stock Shares Outstanding	0.97	0.39	0.97	0.97	0.97	-0.58	-0.41	-0.89	0.19	0.52	0.97	0.76	0.84	0.95		-0.23	0.78	0.97	0.64	0.84	0.45	0.98	0.76	0.87	0.22	0.58
Non Current Liabilities Total	-0.19	0.54	-0.24	-0.23	-0.24	0.33	0.04	0.36	-0.21	0.07	-0.29	0.05	-0.11	-0.24	-0.23		-0.07	-0.29	0.51	-0.11	-0.01	-0.29	-0.38	-0.19	-0.14	0.28
Other Current Assets	0.89	0.56	0.68	0.73	0.89	-0.52	-0.78	-0.63	0.37	0.83	0.75	0.78	0.96	0.87	0.78	-0.07		0.73	0.65	0.96	0.72	0.79	0.37	0.96	-0.17	0.6
Other Stockholder Equity	0.95	0.33	0.98	0.98	0.94	-0.64	-0.29	-0.96	0.23	0.42	0.98	0.66	0.79	0.9	0.97	-0.29	0.73		0.6	0.79	0.43	0.97	0.83	0.82	0.23	0.55
Total Liab	0.66	0.69	0.64	0.65	0.62	-0.33	-0.26	-0.52	0.08	0.4	0.61	0.71	0.68	0.58	0.64	0.51	0.65	0.6		0.68	0.42	0.59	0.4	0.63	0.12	0.65
Total Current Assets	0.92	0.6	0.75	0.78	0.93	-0.45	-0.73	-0.7	0.22	0.79	0.78	0.81	1.0	0.92	0.84	-0.11	0.96	0.79	0.68		0.59	0.86	0.41	1.0	-0.2	0.67
Short Term Debt	0.56	0.18	0.37	0.46	0.56	-0.3	-0.64	-0.34	0.24	0.62	0.47	0.47	0.59	0.44	0.45	-0.01	0.72	0.43	0.42	0.59		0.39	0.2	0.58	-0.01	0.06
Common Stock	0.97	0.41	0.96	0.96	0.97	-0.6	-0.41	-0.89	0.22	0.53	0.96	0.73	0.86	0.97	0.98	-0.29	0.79	0.97	0.59	0.86	0.39		0.75	0.88	0.14	0.61
Other Liab	0.66	-0.06	0.87	0.86	0.66	-0.78	0.17	-0.88	0.36	-0.07	0.86	0.42	0.41	0.6	0.76	-0.38	0.37	0.83	0.4	0.41	0.2	0.75		0.46	0.65	0.2
Net Tangible Assets	0.94	0.53	0.78	0.8	0.94	-0.5	-0.72	-0.73	0.26	0.77	0.82	0.81	1.0	0.94	0.87	-0.19	0.96	0.82	0.63	1.0	0.58	0.88	0.46		-0.16	0.64
Other Assets	0.04	-0.46	0.34	0.32	0.02	-0.41	0.54	-0.29	0.17	-0.53	0.33	0.06	-0.2	-0.03	0.22	-0.14	-0.17	0.23	0.12	-0.2	-0.01	0.14	0.65	-0.16		-0.31
Long Term Debt	0.63	0.89	0.52	0.5	0.61	-0.25	-0.35	-0.46	0.11	0.54	0.49	0.47	0.67	0.66	0.58	0.28	0.6	0.55	0.65	0.67	0.06	0.61	0.2	0.64	-0.31

Click cells to compare fundamentals

Rocket Pharmaceuticals Account Relationship Matchups

Rocket Pharmaceuticals fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	590.8M	497.0M	551.8M	566.3M	651.3M	683.9M
Short Long Term Debt Total	61.7M	22.6M	22.9M	25.0M	28.8M	30.8M
Other Current Liab	23.2M	17.1M	34.2M	45.8M	52.7M	55.3M
Total Current Liabilities	32.6M	22.2M	39.2M	48.5M	55.8M	58.6M
Total Stockholder Equity	503.5M	454.7M	489.7M	492.6M	566.5M	594.8M
Current Deferred Revenue	590K	(482.0)	(36.7M)	(12.8M)	(11.5M)	(10.9M)
Net Debt	(235.4M)	(210.1M)	(117.7M)	(30.9M)	(27.8M)	(29.2M)
Retained Earnings	(322.8M)	(491.9M)	(713.8M)	(959.4M)	(863.4M)	(820.3M)
Accounts Payable	835.0	482.0	36.7M	1.8K	2.0K	1.9K
Cash	297.1M	232.7M	140.5M	55.9M	64.3M	112.7M
Non Current Assets Total	103.5M	105.0M	187.7M	188.1M	216.3M	227.2M
Non Currrent Assets Other	2.0M	1.8M	1.9M	1.9M	2.2M	1.2M
Cash And Short Term Investments	482.7M	388.7M	356.4M	373.2M	429.2M	226.1M
Common Stock Total Equity	452K	548K	610K	645K	741.8K	778.8K
Common Stock Shares Outstanding	55.4M	63.2M	68.1M	84.0M	96.6M	101.4M
Liabilities And Stockholders Equity	590.8M	497.0M	551.8M	566.3M	651.3M	683.9M
Non Current Liabilities Total	54.7M	20.1M	23.0M	25.3M	22.7M	29.4M
Other Current Assets	9.3M	6.6M	7.7M	5.0M	5.8M	3.6M
Other Stockholder Equity	825.8M	946.2M	1.2B	1.5B	1.7B	1.8B
Total Liab	87.3M	42.3M	62.1M	73.8M	84.8M	59.0M
Total Current Assets	487.3M	392.1M	364.1M	378.2M	435.0M	229.0M
Accumulated Other Comprehensive Income	(42K)	(161K)	(357K)	319K	366.9K	385.2K
Short Term Debt	9.4M	5.1M	5.0M	2.7M	3.1M	3.2M
Common Stock	610K	645K	791K	903K	1.0M	1.1M
Other Liab	23K	136K	80K	2.6M	3.0M	3.1M
Net Tangible Assets	307.3M	503.5M	454.8M	424.8M	488.5M	252.1M
Property Plant And Equipment Net	70.6M	72.3M	77.6M	87.6M	100.7M	105.8M
Retained Earnings Total Equity	(105.9M)	(183.1M)	(322.8M)	(491.9M)	(442.7M)	(420.6M)
Short Term Investments	185.6M	156.0M	215.9M	317.3M	364.9M	383.1M
Capital Surpluse	300.3M	489.9M	825.8M	946.2M	1.1B	549.2M
Property Plant And Equipment Gross	70.6M	77.6M	86.7M	101.6M	116.9M	122.7M
Non Current Liabilities Other	19.6M	80K	2.6M	2.9M	3.4M	3.8M
Property Plant Equipment	29.3M	19.2M	72.3M	77.6M	89.3M	93.8M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Rocket Stock Analysis

When running Rocket Pharmaceuticals' price analysis, check to measure Rocket Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rocket Pharmaceuticals is operating at the current time. Most of Rocket Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Rocket Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rocket Pharmaceuticals' price. Additionally, you may evaluate how the addition of Rocket Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC